𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Cancer immunotherapy with interleukin-2-activated natural killer cells

✍ Scribed by Per H. Basse; Theresa L. Whiteside; Ronald B. Herberman

Book ID
111640270
Publisher
Humana Press Inc
Year
2002
Tongue
English
Weight
125 KB
Volume
21
Category
Article
ISSN
1073-6085

No coin nor oath required. For personal study only.

πŸ“œ SIMILAR VOLUMES

Interleukin-2 augments natural killer ce
Interleukin-2 augments natural killer cell activity
✍ Henney, Christopher S.; Kuribayashi, Kagemasa; Kern, Donald E.; Gillis, Steven πŸ“‚ Article πŸ“… 1981 πŸ› Nature Publishing Group 🌐 English βš– 523 KB
Recombinant interleukin 2-activated natu
Recombinant interleukin 2-activated natural killer cells regulate IgG2a production
✍ SebastiΓ‘n Amigorena; Christian Bonnerot; Wolf Herman Fridman; Jean-Luc Teillaud πŸ“‚ Article πŸ“… 1990 πŸ› John Wiley and Sons 🌐 English βš– 622 KB

Laboratoire d'lmmunologie Cellulaire et Clinique, INSERM U.255, Institut Curie, Paris Recombinant interleukin 2-activated natural killer cells regulate IgGza production\* In this report we have analyzed the effect ofrecombinant interleukin 2 (rIL 2) and rIL 2-activated natural killer (NK) cells on

Immunotherapy of cancer with lymphokines
Immunotherapy of cancer with lymphokines and lymphokine-activated killer cells
✍ John W. Yarbro πŸ“‚ Article πŸ“… 1991 πŸ› John Wiley and Sons 🌐 English βš– 996 KB

Our expanding knowledge of the immune system has provided a basis of rationality for immunotherapy . Some non-specific immunotherapy has achieved the status of standard treatment: interferon in hairy cell leukemia and chronic myelogenous leukemia, BCG in bladder cancer, and levamisole in colon cance

The requirements for successful immunoth
The requirements for successful immunotherapy of intraperitoneal cancer using interleukin-2 and lymphokine-activated killer cells
✍ Reyer T. Ottow; Alexander M. M. Eggermont; E. Philip Steller; Paul H. Sugarbaker πŸ“‚ Article πŸ“… 1987 πŸ› John Wiley and Sons 🌐 English βš– 907 KB

In a significant proportion of patients with gastrointestinal and ovarian malignancy the peritoneal cavity is a prominent site at which surgical treatment fails. Adjuvant treatments directed at this site should be investigated in an attempt to improve survival in patients with these cancers. In the